Increased blood pressure (BP), the leading risk for death and disability globally, is estimated to be responsible for almost one in five deaths and an estimated 7% of disability globally.1 In many economically developing regions, the prevalence of hypertension is both high and increasing.2 Globally, it is estimated that approximately one half of people with hypertension are not aware they have it and that fewer than 20% have controlled BP.2, 3, 4 The epidemic of noncommunicable diseases (NCDs) that are driven by hypertension, tobacco, unhealthy diets, physical inactivity, excess alcohol, obesity, and diabetes is viewed as a threat to the world's development and economies apart from the widespread social and personal distress that NCDs cause.5
It is dismaying to realize that, with the current knowledge, these NCD risks, specifically with respect to hypertension, are largely preventable and treatable. The World Health Organization (WHO) has outlined a series of public health policies to promote healthy diets, physical activity, lower alcohol consumption, and a tobacco‐free environment that would largely prevent blood pressure‐related disease burden and most NCDs if fully implemented.6 Specifically, dietary sodium is highly relevant to the hypertension community as the primary adverse effect of excess dietary salt is mediated through increased BP and attributed to nearly one third of hypertension cases.7 Clinically, controlling hypertension can also prevent its adverse health consequences (although it will not impact patients with suboptimal but normal BP wherein half of BP‐related risk resides).8 From a clinical perspective, the issue put simply is to screen BP at all encounters, diagnose patients with high BP, and treat patients to control.
Underlying the simplicity of the above is the high complexity of influencing, developing, and implementing public health policy; changing community structure, values, and resources; enhancing public self‐efficacy; providing comprehensive primary health care service delivery; ensuring health care providers have the information they need; and surveillance, monitoring, and evaluation to determine what is working and what is not.9 This speaks to the need for comprehensive systematic plans for the prevention and control of hypertension. Several high‐resource countries have developed or are in the process of developing systematic plans for hypertension control.7, 9, 10 Notably, it is the United States and Canada that have long histories of developing and updating such strategies that have the highest rates of hypertension control.9, 11 From these “Best Practices” and lessons learned, strides can be made in translating hypertension prevention and control to all populations.
Strategic planning can be developed by either governments or nongovernmental organizations such as national hypertension societies or preferably through partnership of government and nongovernmental organizations. Strategies focusing on hypertension are perhaps the most feasible and impactful starting point to prevent and control NCDs (arguably competing with tobacco for most impactful health intervention). Several countries have cardiovascular programs that incorporate hypertension prevention and control, while the WHO advocates hypertension integration into NCD prevention and control strategies for low‐resource settings.12 Since the most appropriate strategy is likely to depend on the specific national situation, hypertension organizations have a social responsibility to ensure that hypertension prevention and control is prominent and specifically featured in national NCD or cardiovascular strategies. In this regard, the need for focused hypertension strategies is advocated by the World Hypertension League (WHL). Specifically, that in both low‐ to middle‐resource settings and many high‐resource settings, the most appropriate approach is to incorporate the hypertension strategy into a more comprehensive approach. Further, if a hypertension strategy is the primary starting focus, the ultimate plan should be eventual integration with other risks and diseases. With this framework, the WHL specifically challenges all national hypertension and cardiovascular organizations to develop focused hypertension strategies that can stand alone or are a part of a more comprehensive approach to prevent NCDs.
In developing a strategy, the first step is to consider the context. Is the strategy for the organization's internal use, to use for advocacy to outside organizations, to improve hypertension prevention and control in the population, or even broader to prevent and control NCDs? Is it limited in scope, focusing on clinical control, or is it intended to also address prevention? What are the baseline hypertension data for the population, perhaps using data from the Global Burden of Disease Survey? The scope of the strategy will dictate the different partner organizations that are required for implementation. In general, organizations (ie, primary care) that are impacted by a strategy are much more likely to be supportive if they were involved in the development. Involving governmental organizations is likely critical if the strategy is to involve changes in health policy and the health care system or require substantive governmental resources.
The strategy should set targets for achieving improvements in prevention and control, outline the actions that will allow achievement of those targets, and outline the available indicators that will track progress toward the targets.
There are several hypertension strategies that hypertension organizations can use as templates.7, 9, 10, 12, 13, 14 All strategies require adaptation to the national or regional circumstances based on cultures, values, health literacy, health care systems, and available resources. A commonly used framework in high‐ and low‐resource settings is the Wagner Expanded Chronic Care Model, which the WHL used in developing a hypertension strategy template.15 The WHL has a Powerpoint slide set (www.whleague.org) to support strategic planning that can be adopted to meet the needs of the setting. Some examples of the interventions national organizations can include in their strategic plans under each category in the Wagner model are provided in the Table. Hypertension organizations may find it is most feasible by initially focusing on the health systems or information systems components of the strategy. Simple guidance aimed at primary care settings and utilizing care algorithms are key components and can be adapted from those of the WHO.12 It is paramount that those in low‐resource settings be cognizant of the need to target scarce health care system resources to those at highest risk.12 Strategies that are clinically focused can still indicate the importance of public health policies to prevent hypertension.
Table 1.
Examples of Actions That Could Be Advocated for Hypertension Prevention and Control Using the Wagner Expanded Chronic Care Model as a Framework15
| Parameter | Examples of Actions | |
|---|---|---|
| Build Healthy Public Policy | National policy to have targets and timelines for reducing salt additives to foods | Consideration of health in all government polices |
| Create supportive environments | Healthy low‐salt foods readily available and affordable to the full population | Fresh fruits and vegetables readily available and affordable to the full population |
| Strengthen community actions | Safe accessible places to be physically active | High capacity to regularly screen blood pressure in the full population |
| Self‐management/develop personal skills | Education about healthy eating, cooking, physical activity, healthy body weight, and smoking and alcohol consumption in schools | Personalized information about hypertension management and training to gain skills for all people diagnosed with hypertension |
| Delivery system design/reorient health services | Available, affordable, high‐quality antihypertensive medications for the full population | Strong interdisciplinary primary care teams with capacity to manage noncommunicable diseases and their risks |
| Decision support | Simple care algorithm spanning screening, diagnosis, treatment, and control | Health records that incorporate care algorithm and track key hypertension indicators at the clinic level |
| Information systems | Regular population health surveys that track hypertension prevalence, awareness, treatment, and control in key populations | Standardized analysis for key hypertension indicators with broad dissemination of the findings to decision makers in public and clinical health |
Summary
Random, unplanned actions and interventions along with extensive speciality‐focused clinical guidelines have not substantively impacted hypertension prevalence and control. The WHL strongly advocates strategic planning exercises for national and regional organizations that have hypertension as a major focus. Set aspirational targets for prevention and control and, at a minimum, plan to achieve the United Nations targets of a 25% reduction in uncontrolled hypertension and a 30% reduction in dietary salt by 2025 (Table).6, 16
Statement of Financial Disclosure
Dr M. Niebylski and K. Redburn are paid contractors for the World Hypertension League but have no other conflicts. All other authors have no disclosures or other conflicts to declare.
References
- 1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2224–2260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380:611–619. [DOI] [PubMed] [Google Scholar]
- 3. Lloyd‐Sherlock P, Beard J, Minicuci N, et al. Hypertension among older adults in low‐ and middle‐income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43:116–128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Tibazarwa KB, Damasceno AA. Hypertension in developing countries. Can J Cardiol. 2014;30:527–533. [DOI] [PubMed] [Google Scholar]
- 5. Global Risk Network of the World Economic Forum . Global Risks 2009 ‐ A Global Risk Network Report. World Economic Forum, 3‐34. Cologny/Geneva, Switzerland: World Economic Forum; 2009. [Google Scholar]
- 6. World Health Organization . WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Report, III‐103. Geneva, Switzerland: WHO Press, World Health Organization; 2013. [Google Scholar]
- 7. Committee on Public Health Priorities to Reduce and Control Hypertension in the U.S.Population, Institute of Medicine of the National Academies . A Population‐Based Policy and Systems Change Approach to Prevent and Control Hypertension. Report, v‐173. Washington, DC: National Academies Press; 2010. [PubMed] [Google Scholar]
- 8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Campbell N, Young ER, Drouin D, et al. A framework for discussion on how to improve prevention, management and control of hypertension in Canada. Can J Cardiol. 2012;28:262–269. [DOI] [PubMed] [Google Scholar]
- 10. Developed together by the 12 member organisations of the Blood Pressure System Leadership Board. Tackling high blood pressure: From evidence into action. Public Health England 2014;1–44.
- 11. Kostis WJ, Thijs L, Richart T, et al. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure‐lowering medications. Hypertension 2010; 56: 1060–1068. [DOI] [PubMed] [Google Scholar]
- 12. World Health Organization . WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low‐Resource Settings. Report, 1–65. Geneva, Switzerland: WHO Press, World Health Organization; 2010. [Google Scholar]
- 13. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878–885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Maryon‐Davis A, Press V. Easing the pressure: tackling hypertension. C: Developing a local hypertension strategy. In: Wordworks L, ed. Report, 33–60. UK: Faculty of Public Health and the National Heart Forum; 2005. [Google Scholar]
- 15. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998;1:2–4. [PubMed] [Google Scholar]
- 16. Miller WR, Rollnich S. Motivational Interviewing: Preparing People for Change. New York, NY: Guilford Press; 2002. [Google Scholar]
